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Abstract
Background: The thyroid stimulating hormone receptor (TSHR) gene is an established susceptibility locus for Graves’
disease (GD), with recent studies refining association to two single nucleotide polymorphisms (SNPs), rs179247 and
rs12101255, within TSHR intron 1.
Methodology and Principal Findings: We aimed to validate association of rs179247 and rs12101255 in Polish and UK
Caucasian GD case-control subjects, determine the mode of inheritance and to see if association correlates with specific GD
clinical manifestations. We investigated three case-control populations; 558 GD patients and 520 controls from Warsaw,
Poland, 196 GD patients and 198 controls from Gliwice, Poland and 2504 GD patients from the UK National collection and
2784 controls from the 1958 British Birth cohort. Both rs179247 (P=1.2610
22–6.2610
215, OR=1.38–1.45) and rs12101255
(P=1.0610
24–3.68610
221, OR=1.47–1.87) exhibited strong association with GD in all three cohorts. Logistic regression
suggested association of rs179247 is secondary to rs12101255 in all cohorts. Inheritance modeling suggested a co-dominant
mode of inheritance in all cohorts. Genotype-phenotype correlations provided no clear evidence of association with any
specific clinical characteristics.
Conclusions: We have validated association of TSHR intron 1 SNPs with GD in three independent European cohorts and
have demonstrated that the aetiological variant within the TSHR is likely to be in strong linkage disequilibrium with
rs12101255. Fine mapping is now required to determine the exact location of the aetiological DNA variants within the TSHR.
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Introduction
The thyroid stimulating hormone receptor (TSHR) is primarily
expressed on the thyroid follicular cell surface membrane and via
its ligand, TSH, is one of the key regulators of thyroid growth and
hormone production. TSHR autoantibodies with either stimula-
tory (TSAb) or blocking (TBAb) activity are a key feature of
autoimmune thyroid disease (AITD), with TSAb having a pre-
dominant effect in Graves’ disease (GD) leading to hyperthyroid-
ism [1]. Genetic variation within the TSHR region may influence
TSHR structure, expression and/or post-translational processing,
which in turn could initiate or exacerbate the autoimmune
response against the TSHR in GD.
Original TSHR genetic studies focused on several non-
synonymous single nucleotide polymorphisms (nsSNPs) and
despite a number of studies, no replicable GD associations
emerged [2–8]. Genome wide linkage analysis subsequently
suggested a GD locus in this chromosome region [9]. Later
association screening by two independent studies identified strong
association within TSHR intron 7 in Japanese and TSHR intron 1
in UK Caucasian cohorts, which provided the first convincing
evidence for TSHR association with GD [10,11]. The Wellcome
Trust Case Control Consortium (WTCCC) identified association
of a further TSHR nsSNP rs3783941 (Arg248Ser) with GD in a
genome wide screen of 15,000 nsSNPs in 900 UK Caucasian GD
cases and 1500 controls [12]. Recent detailed association mapping
of 98 SNPs across 800Kb of the TSHR region, refined association
to within 40Kb of TSHR intron 1 in 768 GD patients and 768
controls of UK Caucasian origin [13]. Strongest SNP associations
were rs179247 (P=8.9610
28, OR=1.53) and rs12101255
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27, OR=1.55), with logistic regression suggesting
these SNPs or variants in strong linkage disequilibrium (LD) may
drive the association signal in the region [13]. Furthermore,
rs179247 and rs12101255 were associated with reduced expression
of full length TSHR mRNA relative to two truncated splice
variants in thyroid tissue [13]. The aim of the current study was to
determine whether rs179247 and rs12101255 were also associated
with GD in two Polish case-control collections. Our secondary aim
was to further investigate association in an extended UK cohort,
combined with detailed inheritance and logistic regression analysis
to attempt to split association between these two SNPs. Finally,
sub-phenotype analysis was performed to look for association with
specific GD clinical characteristics.
Methods
All GD patients in the cohorts investigated in the current study
were unrelated and gave informed written consent and the project
was approved by the relevant local research committees, including;
the South Birmingham Research Ethics committee (MRec/01/7/
60), Medical Research Centre, Polish academy of science ethics
committee and the Maria Sklodowska-Curie Memorial Cancer
Centre and Institute of Oncology, Gliwice Branch ethics
committee.
Subjects
Two independent Polish GD case-control collections were
investigated in the current study. The first, from Warsaw, included
558 Caucasian GD patients recruited from the Department of
Endocrinology, Medical University of Warsaw, Poland. The second
was from Gliwice, and consisted of 196 Caucasian GD patients,
ascertained at the Department of Nuclear Medicine and Endocrine
Oncology, Centre of Oncology, Gliwice, Poland. Criteria for
clinical diagnosis were the same for both collections, which were
based on clinical and biochemical evidence of hyperthyroidism,
confirmed by the presence of diffuse goiter, detectable TSHR
autoantibodies (TRAK Lumitest, B.R.A.H.M.S Diagnostica
GmbH, Germany) and/or increased radioiodine uptake, as
described previously [14]. The severity of ophthalmopathy was
assessed according to the NOSPECS classification, with patients $
NOSPECS class III considered clinically evident. Independent,
geographically matched control groups were recruited for each of
the two cohorts (Warsaw and Gliwice). The Warsaw control group
contained 520 anonymous unrelated Polish adults selected from a
national repository, in-part established for case-control studies [15].
The Gliwice control group consists of 198 healthy subjects with no
family history of GD or other autoimmune disorder, as described
previously [16]. All control groups were established for case-control
association studies and have been widely investigated and
characterised previously [15,16].
The UK cohort consisted of 2504 GD patients which make up
part of the AITD UK national collection. Of these, 308 GD
patients were investigated previously [13] with an additional 2196
GD patients from the UK national collection also investigated
[17]. In addition, 2784 geographically matched controls were
obtained from the 1958 British Birth Cohort (1958 BBC) [18].
The clinical characteristics of both the Polish and UK GD
National collection are displayed in Table S1.
Genotyping
Genotyping of rs179247 and rs12101255 was performed using
TaqManH SNP genotyping technology (Applied Biosystems,
Foster City, USA) according to the manufacturer’s protocol,
independently in the three respective centres.
Statistical analyses
Prospective power calculations in both Polish and UK cohorts
demonstrated we had .99% power (a=0.05) to detect a
significant difference in allele frequencies between cases and
controls, assuming an OR=1.50 as reported previously [13]. To
ensure genotyping accuracy Hardy-Weinberg equilibrium (HWE)
was calculated for all cohorts, with P,0.05 considered indicative
of deviation from HWE. Allele and genotype association tests
assuming recessive, dominance and co-dominance were compared
between GD cases and controls using the Chi-squared test of
significance within the Statistica (StatSoft Inc., Tulsa, USA)
statistical package. LD between the two SNPs was measured using
the pairwise LD measures D’ and r
2 and LD blocks were
subsequently defined using the Gabriel et al algorithm [19]. Briefly,
this algorithm calculates 95% confidence intervals (CI) of D’ for
each pair of loci and subsequently groups sets of markers into
either; ‘‘strong LD’’ or ‘‘strong recombination’’ based on the 95%
CI [19]. Strong LD is defined if the upper 95% CI has a D’.0.98
and the lower D’ CI is $0.7 [19]. Strong recombination is defined
when the D’ upper 95% CI is D’,0.9. Each LD block is defined
when 95% or more of the region is classified as pairwise ‘‘strong
LD’’. The algorithm allows for 5% of an LD block to show some
evidence of recombination [19]. Based on this LD block definition
haplotype counts of GD cases and controls were constructed and
analysed for association within the computer program Haploview
version 4.2, which employs an expectation maximization algo-
rithm (http://www.broad.mit.edu/mpg/haploview) [20]. Logistic
regression analysis was performed using the SPSS statistical
package (SPSS, UK) within the Polish cohorts and the PLINK
statistical package was used in the UK [21].
Clinical Phenotypes
Association analysis of rs179247 and rs12101255 with specific
clinical manifestations of GD were performed in all 3 cohorts for;
age of GD diagnosis (#30 years vs $31 years), severity of
ophthalmopathy based on NOSPECS classification (NOSPECS 0
–1vs NOSPECS 2 – 6) and smoking status (smokers vs non-
smokers).
Results
Allele and genotype distribution
GD cases and controls in all 3 cohorts were within HWE
(P.0.05). In the Warsaw and Gliwice cohorts allele A of rs179247
was more frequent in GD patients (P=6.0610
25–9.0610
23 and
OR=1.42–1.45). Similarly, the T allele of rs12101255 displayed an
increased frequency in both Warsaw and Gliwice GD patients
compared to controls (P=3.0610
25–4.0610
25, OR=1.47–1.87,
respectively)(Table1).Astherewasnosignificantdifferenceinallele
frequencies of rs179247 and rs12101255 between the Warsaw and
Gliwice cohorts (P.0.05) we combined the two Polish cohorts
(GD=754, controls=718), further confirming strong association
for rs179247 (P=3.00610
26, OR=1.43 [95% CI=1.23–1.65])
and rs12101255 (P=1.00610
27, OR=1.57 [95% CI=1.34–
1.84]) (Table 1).
To further investigate association and interaction between the
two markers, we investigated rs179247 and rs12101255 in a GD
data set from the UK national collection of AITD patients. Both
SNPs demonstrated strong association in the UK data set with
rs179247 allele A (P=8.60610
214, OR=1.38 [95% CI=1.27–
1.49]) and rs12101255 allele T (P=4.14610
220, OR=1.49 [95%
CI=1.37–1.61]). To determine whether the strong associations
could be explained by either a dominant or recessive effect, we
modeled the mode of inheritance for these variants and found that
TSHR Association with GD in 3 Caucasian Cohorts
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suggesting a co-dominant effect within the region (Table S2).
Haplotypes
The two SNPs demonstrated strong but incomplete LD
(D’=0.98 and r
2=0.50), with three common (minor allele
frequency (MAF) $0.11) haplotypes observed (Table 2). The
strongly associated alleles at each individual SNP locus, rs179247
(A) and rs12101255 (T) form a single haplotype (haplotype
number 1) demonstrating the strongest association with GD in all
populations (Combined Polish P=2.0610
28, UK cohort
P=3.2610
221). Interestingly, if the associated allele at
rs12101255 was changed to the non-associated rs1210255 (C)
and rs179247 (A) remained the same (haplotype 2) there was no
association in any population (Combined Polish P=0.57, UK
cohort P=0.05), suggesting rs12101255 (A) may drive the
Table 1. TSHR genotype and allele frequencies in Warsaw, Gliwice, combined Polish cohorts and UK case-control cohorts.
TSHR SNP Cohort Alleles/Genotypes Controls (%) GD (%) P OR 95% CI
rs179247: Warsaw AA 81 (15.6) 139 (24.9) 2.0610
24 1.42 1.20–1.68
AG 259 (49.0) 270 (48.8)
GG 180 (34.6) 149 (26.7)
A 421 (40.5) 548 (49.1) 6.0610
25
G 619 (59.5) 568 (50.9)
Gliwice AA 34 (17.1) 58 (29.6) 1.2610
22 1.45 1.10–1.93
AG 98 (49.2) 84 (42.9)
GG 67 (33.7) 54 (27.6)
A 166 (41.7) 200 (51.0) 9.0610
23
G 232 (58.3) 192 (49.0)
Polish Cohorts Pooled AA 115 (16.0) 197 (26.1) 3.0610
26 1.43 1.23–1.65
AG 356 (49.7) 354 (46.9)
GG 247 (34.4) 203 (26.9)
A 586 (40.8) 748 (49.6) 2.0610
26
G 850 (59.2) 760 (50.4)
UK GD National Collection AA 737 (29.0) 879 (37.6) 8.6610
214 1.38 1.27–1.49
AG 1243 (48.9) 1110 (47.4)
GG 561 (22.1) 351 (15.0)
A 2717 (53.5) 2868 (61.3) 6.2610
215
G 2365 (46.5) 1812 (38.7)
rs12101255: Warsaw TT 35 (6.7) 75 (13.4) 1.0610
24 1.47 1.23–1.77
TC 212 (40.8) 245 (43.9)
CC 273 (52.5) 238 (42.7)
T 282 (27.1) 395 (35.4) 3.0610
25
C 758 (72.9) 721 (64.6)
Gliwice TT 17 (8.6) 32 (16.3) 2.0610
24 1.87 1.39–2.53
TC 71 (35.9) 94 (48.0)
CC 110 (55.6) 70 (35.7)
T 105 (26.5) 158 (40.3) 4.0610
25
C 291 (73.5) 234 (59.7)
Polish Cohorts Pooled TT 52 (7.2) 107 (14.2) 1.0610
27 1.57 1.34–1.84
TC 283 (39.4) 339 (45.0)
CC 383 (53.3) 308 (40.8)
T 387 (27.0) 553 (36.7) 2.0610
28
C 1049 (73.1) 955 (63.3)
UK GD National Collection TT 338 (13.4) 482 (20.9) 4.14610
220 1.49 1.37–1.61
TC 1148 (45.3) 1136 (49.3)
CC 1046 (41.3) 687 (29.8)
T 1824 (36.0) 2100 (45.6) 3.68610
221
C 3240 (64.0) 2510 (54.4)
Both SNPs are displayed 59 –3 9 on the positive DNA strand. P-values generated via chi-squared (x
2) tests for both alleles (262) and genotypes (co-dominant) are
displayed. The odds ratios (ORs) and 95% CI have been calculated from the minor allele in each SNP.
doi:10.1371/journal.pone.0015512.t001
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rs179247 (G) – rs12101255 (C) make up haplotype number 3 and
display an increased frequency incontrols compared to GD patients.
Logistic Regression Analysis
Since haplotype analysis suggested an important role for
rs12101255 in driving association, we performed logistic regression
to try and split association between the two SNPs. In both the
combined Polish data set and in the UK national collection both
SNPs demonstrated strong association when entered into the model
(co-dominant), as expected. However, after conditioning on each
SNP, rs12101255 remained associated after conditioning for
rs179247 (Polish P=2.0610
23, UK P=4.23610
28), whereas
rs179247 became non-associated after conditioning for
rs12101255 (Polish P=0.36, UK P=0.16). This suggests associa-
tion at rs179247 maybe driven by rs12101255 or that rs12101255 is
in stronger LD with the aetiological variants within the region.
Genotype phenotype correlations
We looked for replicable clinical phenotype associations with
the two SNPs across all 3 cohorts. The non-associated G allele of
rs179247 displayed a slight increase in frequency in smokers
compared to non-smokers, although this association was not
replicated across all 3 cohorts. No other clinical associations were
detected across any of the 3 cohorts (Tables S3 and S4).
Discussion
The present study provides convincing replication and further
association mapping of TSHR intron 1 association with GD in
European Caucasians. The minor alleles of rs179247 (A) and
rs12101255 (T) were increased in GD patients compared to
controls with mode of inheritance suggesting a co-dominant effect.
The magnitude of genetic effects observed in the current study are
similar (OR<1.50) to those observed in the original report [13],
confirming that the TSHR represents a major susceptibility locus
for GD in-line with other previously identified non-HLA
susceptibility loci [22] including CTLA4 [23] and PTPN22 [24].
We were unable to identify any convincing, replicable evidence for
genetic association with any specific GD clinical features. An
increased frequency of the non-associated G allele in smokers of
the Warsaw cohort represented the only association identified,
however this failed replication in all other cohorts. This maybe
because GD represents a heterogeneous disorder with various GD
specific clinical features, which may require even larger disease
cohorts to detect such effects if they exist.
Previous Japanese investigations identified numerous SNPs
within TSHR introns 7 and 8 strongly associated with GD [11].
However, more recent screening of an extended region of the
TSHR (800Kb) implementing Tag SNPs in a UK Caucasian
cohort, ruled out any association within introns 7–8 in Caucasians
[13]. The current study replicates and furthers our understanding
Table 2. Haplotype association tests between TSHR rs179247 and rs12101255 SNPs.
Cohorts TSHR SNP Allele
Haplotype
Number
Controls
Frequency GD Frequency P OR 95% CI
Warsaw rs179247 A 1 26.9 35.1 5.0610
25 1.45 1.21–175
rs12101255 T
Gliwice rs179247 A 1 26.3 40.2 4.0610
25 1.84 1.36–2.49
rs12101255 T
Polish Cohorts Pooled rs179247 A 1 26.8 36.4 2.0610
28 1.55 1.32–1.81
rs12101255 T
UK GD National Collection rs179247 A 1 36.0 45.0 3.2610
221 1.47 1.36–1.59
rs12101255 T
Warsaw rs179247 A 2 13.7 14.3 0.67 - -
rs12101255 C
Gliwice rs179247 A 2 15.4 11.0 0.07 - -
rs12101255 C
Polish Cohorts Pooled rs179247 A 2 14.2 13.5 0.57 - -
rs12101255 C
UK GD National Collection rs179247 A 2 17.0 16.0 0.05 - -
rs12101255 C
Warsaw rs179247 G 3 59.4 50.6 4.0610
24 0.70 0.59–0.83
rs12101255 C
Gliwice rs179247 G 3 58.2 48.9 8.0610
23 0.70 0.53–0.92
rs12101255 C
Polish Cohorts Pooled rs179247 G 3 59.1 50.2 1.0610
26 0.70 0.60–0.81
rs12101255 C
UK GD National Collection rs179247 G 3 46.0 39.0 1.0610
215 0.72 0.67–078
rs12101255 C
The frequency of the 3 haplotypes between rs179247 and rs12101255 in GD cases and controls in 3 independent cohorts and combined Polish cohort are displayed. The
P-value of the Chi-squared (x
2) test is displayed, with respective Odds ratios (OR) and 95% CI for haplotypes showing evidence for association (P,0.05) with GD.
doi:10.1371/journal.pone.0015512.t002
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Further studies are now required in Japanese and other ethnic
backgrounds to independently confirm previous reports of
association within TSHR intron 7. Indeed, it should be noted that
Hiratani et al investigated 3 variants within intron 1 and identified
some evidence of association with TSHR intron 1 SNP, rs2268474
(P=0.026) in the Japanese [11]. It is particularly important that
these findings are confirmed, since it could have future
implications on the usefulness of exploiting different LD structures
among different ethnic groups (trans-ethnic mapping), to refine
genetic association.
Since rs179247 and rs12101255 are located 18.5Kb apart
within TSHR intron 1 we attempted to resolve the issue of whether
the two SNPs had independent effects or if the effect of one SNP
was secondary to LD with the other. Logistic regression in all
cohorts suggested that the effect of rs179247 could be secondary to
rs12101255. This conclusion was consistent with single SNP
analysis, which demonstrated a greater magnitude of genetic
association with rs12101255 compared to rs179247 in all our
cohorts. Furthermore, haplotype analysis demonstrated that the
associated allele T of rs12101255 drives the highly associated
haplotype of rs179247 (A) and rs12101255 (T). The increased size
of the National AITD cohort of 2504 GD patients compared to
the smaller dataset of 768 UK Caucasian GD investigated
previously has allowed differentiation between these two highly
associated SNPs [13].
In conclusion, our results confirm strong association of TSHR
intron 1 SNPs with GD in three European Caucasian data sets and
for the first time association in Polish GD subjects. Detailed
investigation of all genetic variants within the region to identify the
aetiological variant/s is now required, which may lead to advances
towards developing TSHR targeted therapeutics.
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Table S1 Clinical Characteristics of Polish GD patients
from the Warsaw and Gliwice cohorts and the UK GD
National Collection. Shows the number of patients and
percentage in brackets where appropriate, possessing specific
GD clinical phenotypes in Warsaw, Gliwice Polish cohorts and
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Table S2 Association test results for rs179247 and
rs12101255 assuming either dominant or recessive
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Table S3 Shows the genotypes of rs179247 with specific
GD clinical features. Each clinical feature is compared with
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following segregations; age of GD onset (,30 years old vs $30
years old), severity of ophthalmopathy determined by NOSPECS
classification (NOSPECS ,2 vs NOSPECS $2), smoking status
(current or previous smoker vs non-smoker) and in the UK GD
National Collection cohort only, thyroid antibody status whether
positive for one of either thyroid peroxidise, thyroglobulin or
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specific GD clinical features. Each clinical feature is
compared with genotype counts in the both two Polish and UK
cohorts, using the following segregations; age of GD onset (,30
years old vs $30 years old), severity of ophthalmopathy
determined by NOSPECS classification (NOSPECS ,2v s
NOSPECS $2), smoking status (current or previous smoker vs
non-smoker) and in the UK GD National Collection cohort only,
thyroid antibody status whether positive for one of either thyroid
peroxidise, thyroglobulin or TSHR (positive vs negative) and
presence or abscence of a difuse, palpable goitre (presence vs
abscence). The Chi-squared test P-value comparing genotype and
allele counts is displayed. *=P,0.05.
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